Direct answer. Heart failure with preserved ejection fraction, or HFpEF, is a clinical heart-failure syndrome despite a relatively preserved left-ventricular pumping fraction. Abnormal filling and pressures can matter even when the percentage expelled appears reassuring. It requires a clinical work-up; normal-range fraction alone does not diagnose or exclude HFpEF. Confidence is high in these distinctions; this guide does not independently certify every underlying treatment trial. NHLBI heart failure causes and ventricular types.
- “Preserved” refers to the expelled fraction, not proof that all cardiac function is normal.
- Breathlessness requires a differential diagnosis; not every symptom with a preserved fraction is HFpEF.
- Hypertension, metabolic conditions, rhythm and other causes or comorbidities need evaluation.
- Current guidance includes selected SGLT2 and mineralocorticoid-receptor treatment alongside congestion and cause management; older “only diuretics” wording is incomplete.
- Fluid, salt and exercise advice must fit the individual findings and monitored care.
Evidence summary
| Question | Source role | Conclusion and confidence |
|---|---|---|
| Does preserved fraction mean no failure? | NHLBI filling/function education | No. Important filling and pressure abnormalities can coexist. High confidence. |
| Is breathlessness plus a normal fraction sufficient? | Clinical diagnostic context | No. Alternative causes and supporting cardiac findings matter. |
| Is treatment limited to a water tablet? | Current NICE context | No. Current care includes selected disease-management options and management of associated conditions. |
| Can supplement evidence replace a drug trial? | Independent evidence boundary | No fully screened supplement replacement regimen established here. |
Confidence is high in the condition distinctions and need for appropriate assessment. The treatment section attributes clinical guidance; it does not certify the funding of every underlying intervention trial. Independent comparative outcome certainty and a supplement replacement regimen were not established by this focused review. A public institution or independent review cannot make a sponsored original trial financially independent.
What it is
The heart must both accept blood and eject it. A ventricle that does not relax or fill appropriately can produce a heart-failure syndrome while expelling a preserved percentage of the blood it contains. The fraction is therefore useful, but it is not a complete measurement of circulating volume, filling pressure or exercise tolerance. NHLBI heart failure causes and ventricular types.
HFpEF is a clinical diagnosis. The history, examination and imaging findings are assessed with blood testing and possible alternative explanations for symptoms. A reported percentage cannot be used as an online rule that everyone above it either has HFpEF or is free of heart disease. NHLBI heart failure diagnosis.
How it works
High blood pressure and conditions such as obesity and diabetes can contribute to a heart that fills less effectively. The syndrome is heterogeneous: accompanying rhythm, coronary, valve, kidney or specific muscle disease can influence the assessment and care. A contributing risk factor is not enough to prove the precise cause in one person. NHLBI heart failure causes and ventricular types.
Breathlessness, fatigue and swelling may reflect congestion or limited reserve, but they can also arise from other illnesses. Symptoms may vary with activity and time. That makes a cause-specific evaluation more useful than assigning every episode of exhaustion in an older adult to HFpEF or to anxiety. NHLBI heart failure symptoms.
The evidence-based treatments
Current NICE NG106 recommends considering a mineralocorticoid receptor antagonist and an SGLT2 inhibitor for preserved-fraction heart failure, with linked technology appraisals and individual eligibility. Congestion treatment and management of associated conditions remain important. This is attributed care guidance, not a personal prescription or an independent product ranking; original financial chains are not all cleared here. NICE NG106 chronic heart failure recommendations.
Diuretics may relieve fluid accumulation, and the team also addresses the documented blood-pressure, rhythm, coronary, valve or other problem. The older March 2022 NHLBI treatment page describes diuretics as the main preserved-fraction treatment; that wording is not used as a current complete options list. Risks and monitoring still depend on the actual medicine and physiology. NHLBI heart failure treatment.
Supplement and lifestyle evidence
Ask for rehabilitation or safe activity advice and help addressing relevant smoking, sleep or metabolic risks. NICE advises against routine fluid or sodium restriction for everyone with heart failure; the individual assessment can justify changes. Potassium-containing salt substitutes also need review. A restrictive diet or supplement product is not a diagnostic test. NHS heart failure June 2026 education; NICE NG106 chronic heart failure recommendations.
No supplement is established here as a treatment for heart failure with preserved ejection fraction. “Heart support,” improved vessel relaxation, a changed blood marker and fewer clinical events are different claims. The cited source set does not provide a fully financially screened trial basis for replacing diagnosis or prescribed care. Correcting a clinician-confirmed deficiency is a separate indication; a retail blend is not a diagnostic test or an emergency treatment.
What works and what does not
Useful care explains the evidence for the heart-failure diagnosis, its likely contributors and the goals of treatment. Congestion, exercise limitation, rhythm problems and other diseases may need different interventions. A symptom change or a favourable biomarker alone cannot establish every clinical outcome claimed for a product. NHLBI heart failure diagnosis.
Ask which outcome is being pursued: symptoms, physiological findings, recurrence, hospital admission or survival. A plan should also say how adverse effects and deterioration will be recognized. Personal stories and before-and-after readings cannot separate treatment effects from the natural course, other medicines or selection of patients. Manufacturer or materially conflicted outcome claims do not determine this article’s independent verdict.
Risks and side effects
Severe difficulty breathing, an unresponsive collapse or a pale, blue or grey appearance during serious illness needs emergency help. Sudden weight gain, new breathlessness while lying down or frothy pink sputum requires urgent clinical advice. A preserved percentage on an earlier scan should not lead you to dismiss a new emergency. NHS heart failure June 2026 education.
Medicines affecting fluid, blood pressure and pulse require monitoring. Excessive fluid loss can worsen pressure or kidney function, and some medicines raise potassium or cause an excessively slow rhythm. Devices and procedures have separate infection, bleeding and procedural risks. Discuss the exact proposed treatment rather than treating all heart-failure medicines as one risk category. NHLBI heart failure treatment.
Important interactions
Review prescription medicines, over-the-counter painkillers, supplements and salt substitutes with the clinician or pharmacist. Products can change pressure, fluid balance, kidney function or potassium, which can alter the safety of prescribed treatment. Bring the exact ingredients, rather than relying on a “natural” label. NHLBI living with heart failure.
Bring prescription medicines, non-prescription products, recreational drugs and supplements to the same medication review. Product names alone may hide several active ingredients. The prescriber or pharmacist should check the exact combination and kidney function, rather than treating “natural” as a safety category. Never add a second person’s rescue medicine or stop an important prescribed medicine because an internet list mentions a possible interaction.
Who needs assessment
A clinician interprets echo measurements, natriuretic peptides and other tests with symptoms and examination findings. Further investigation depends on the suspected cause and uncertainty. Bring the symptom timeline, medicines and previous tests rather than choosing a diagnosis from one fraction or blood-test number. NHLBI heart failure diagnosis.
Pregnancy plans, pregnancy, significant kidney disease or another serious illness can change the treatment plan. Tell the team about all medicines and supplements and ask who will coordinate changes. Do not borrow another person’s diuretic or adjust treatment from a single home reading. NHLBI heart failure diagnosis.
Clinician-led use and follow-up
Ask how symptoms, fluid accumulation, blood pressure, kidney function and electrolytes will be reviewed, and what warrants earlier contact. Monitor according to the individual plan; do not adjust diuretics or other medicines from a generic online threshold. Reassessment should also consider whether another cause now explains a new symptom. NHLBI living with heart failure.
This guide gives no personal drug, device or supplement dose. The appropriate plan depends on the established diagnosis, current stability, other illnesses and local services. Ask for a written explanation of the treatment purpose, warning signs, review schedule and contact route for side effects. Clinical monitoring and informed consent should accompany any change; study exposures are not prescriptions.
Animal and in-vitro evidence
Cell and animal experiments on vessel function or cardiac stress can suggest mechanisms. They do not establish safe human dosing, symptom improvement or fewer serious events. A laboratory preparation and a retail product may differ in composition, absorption and exposure. No animal or in-vitro result contributes to the independent clinical verdict in this guide.
Funding and source roles
Who paid for the evidence?
Follow named sources to the funding and relationships disclosed in this article. Numbered article disclosures preserve notes where a source is not identified. A public or university name alone does not establish independence.
View 9 more funding disclosures
This graphic reorganizes the article's disclosures; it is not a new financial audit or independence classification. Highlighted notes show different funding relationships where available. Review funding is separate from underlying trial funding. Disclosure is not proof of falsehood, and no declared conflict is not proof of complete independence.
The financial stakes include lifelong medicines, diagnostic imaging, implanted devices, remote monitoring and advanced cardiac services. Clinical guidance may draw on sponsored original trials, which a public guideline does not make independent. These options are described as care context; materially conflicted outcome claims do not determine the independent verdict.
The condition has no corporate owner. Medicines, diagnostics, devices, procedures and marketed supplements create different revenue incentives. This describes financial interests rather than misconduct. Funding tier evaluates proximity to the subject; A–D credibility assesses transparency, accuracy incentives and remaining uncertainty. An unresolved link stays unresolved, and a provisional public-information label does not clear the trials behind it.
| Source | Funding / backers | Country / jurisdiction | Independence | Credibility / incentives / gaps |
|---|---|---|---|---|
| NHLBI heart failure definition | US federal appropriations; separate Gift Fund accepts donations and bequests, including support for public health information. Budget route; Gift authority. Actual donors, page allocation and underlying trial finances unresolved. | United States; NIH/NHLBI, Bethesda, Maryland; federal jurisdiction. | Tier 1 public education provisionally; donation route and page-specific chain unresolved. | B provisional. Public accountability and educational review favour accuracy; institutional priorities, simplification, dated wording and untraced trial ties remain. Role: Public definition of the syndrome. |
| NHLBI heart failure causes and ventricular types | US federal appropriations; separate Gift Fund accepts donations and bequests, including support for public health information. Budget route; Gift authority. Actual donors, page allocation and underlying trial finances unresolved. | United States; NIH/NHLBI, Bethesda, Maryland; federal jurisdiction. | Tier 1 public education provisionally; donation route and page-specific chain unresolved. | B provisional. Public accountability and educational review favour accuracy; institutional priorities, simplification, dated wording and untraced trial ties remain. Role: Public education about ventricular function and causes. |
| NHLBI heart failure symptoms | US federal appropriations; separate Gift Fund accepts donations and bequests, including support for public health information. Budget route; Gift authority. Actual donors, page allocation and underlying trial finances unresolved. | United States; NIH/NHLBI, Bethesda, Maryland; federal jurisdiction. | Tier 1 public education provisionally; donation route and page-specific chain unresolved. | B provisional. Public accountability and educational review favour accuracy; institutional priorities, simplification, dated wording and untraced trial ties remain. Role: Symptom context, not self-diagnosis. |
| NHLBI heart failure diagnosis | US federal appropriations; separate Gift Fund accepts donations and bequests, including support for public health information. Budget route; Gift authority. Actual donors, page allocation and underlying trial finances unresolved. | United States; NIH/NHLBI, Bethesda, Maryland; federal jurisdiction. | Tier 1 public education provisionally; donation route and page-specific chain unresolved. | B provisional. Public accountability and educational review favour accuracy; institutional priorities, simplification, dated wording and untraced trial ties remain. Role: Imaging, blood tests and clinical interpretation. |
| NHLBI heart failure treatment | US federal appropriations; separate Gift Fund accepts donations and bequests, including support for public health information. Budget route; Gift authority. Actual donors, page allocation and underlying trial finances unresolved. | United States; NIH/NHLBI, Bethesda, Maryland; federal jurisdiction. | Tier 1 public education provisionally; donation route and page-specific chain unresolved. | B provisional. Public accountability and educational review favour accuracy; institutional priorities, simplification, dated wording and untraced trial ties remain. Role: Dated March 2022 treatment and adverse-effect background; not the current complete drug list. |
| NHLBI living with heart failure | US federal appropriations; separate Gift Fund accepts donations and bequests, including support for public health information. Budget route; Gift authority. Actual donors, page allocation and underlying trial finances unresolved. | United States; NIH/NHLBI, Bethesda, Maryland; federal jurisdiction. | Tier 1 public education provisionally; donation route and page-specific chain unresolved. | B provisional. Public accountability and educational review favour accuracy; institutional priorities, simplification, dated wording and untraced trial ties remain. Role: Monitoring and day-to-day care education. |
| NHS heart failure June 2026 education | DHSC funds the national NHS website; its policy states no advertising or corporate sponsorship. Named authors, page-level budget and full underlying trial conflicts unresolved. | United Kingdom; England national public-information service. Other jurisdictions have different services. | Tier 1 public education provisional; not a clearance of original studies. | B provisional. Public-service remit and editorial checks support accuracy; simplification, service priorities and incomplete trial-finance tracing limit inference. Role: June 2026 national clinical and emergency education. |
| NICE NG106 chronic heart failure recommendations | NICE 2025–26 audited accounts identify DHSC grants, NHS fees and other income. Committee financial chain and original intervention trials not fully cleared. | United Kingdom; NICE, London and Manchester; English public guidance with wider UK applications. | Tier 2 institutional fee route; trial and committee relationships unresolved. | B provisional for attributed guidance. Transparent development and public accountability favour accuracy; resource priorities, implementation differences and untraced trial ties remain. Role: Current NG106 recommendations with 2025 update and 2026 appraisal links; attributed care context. |
| NHLBI budget | US federal appropriations; separate Gift Fund accepts donations and bequests, including support for public health information. Budget route; Gift authority. Actual donors, page allocation and underlying trial finances unresolved. | United States; NIH/NHLBI, Bethesda, Maryland; federal jurisdiction. | Tier 3 institutional financial self-disclosure. | B provisional. Direct public financial policy, with legal accountability; actual gift donors and allocations not audited. Financial provenance only. |
| NHLBI Gift Fund | US federal appropriations; separate Gift Fund accepts donations and bequests, including support for public health information. Budget route; Gift authority. Actual donors, page allocation and underlying trial finances unresolved. | United States; NIH/NHLBI, Bethesda, Maryland; federal jurisdiction. | Tier 3 institutional financial self-disclosure. | B provisional. Direct public financial policy, with legal accountability; actual gift donors and allocations not audited. Financial provenance only. |
| NHS national website funding policy | DHSC funds the national NHS website; its policy states no advertising or corporate sponsorship. Named authors, page-level budget and full underlying trial conflicts unresolved. | United Kingdom; England national public-information service. Other jurisdictions have different services. | Tier 3 editorial and financial self-disclosure. | B provisional. Explicit funding policy; actual individual declarations and implementation not audited. Financial provenance only. |
| NICE audited annual report and accounts 2025–26 | NICE 2025–26 audited accounts identify DHSC grants, NHS fees and other income. Committee financial chain and original intervention trials not fully cleared. | United Kingdom; NICE, London and Manchester; English public guidance with wider UK applications. | Tier 3 institutional audited financial self-disclosure. | B provisional for reported grant, fee and other income routes. Institution accounts do not clear committee members, named backers or original intervention-trial funding. Financial provenance only. |
Frequently asked questions
Is HFpEF less important than reduced-fraction failure? The preserved label does not measure the seriousness of symptoms or complications. The complete clinical findings determine severity and care. NHLBI heart failure definition.
Could another illness explain breathlessness? Yes. Cardiac and non-cardiac possibilities need evaluation; a preserved fraction does not settle the differential. NHLBI heart failure diagnosis.
Should I drink more for dizziness or less for swelling? Neither is a universal plan. Ask the team how pressure, congestion, kidney function and medicines affect fluid advice. NHLBI living with heart failure.
Sources and funding notes
- NHLBI heart failure definition — Public definition of the syndrome.
- NHLBI heart failure causes and ventricular types — Public education about ventricular function and causes.
- NHLBI heart failure symptoms — Symptom context, not self-diagnosis.
- NHLBI heart failure diagnosis — Imaging, blood tests and clinical interpretation.
- NHLBI heart failure treatment — Dated March 2022 treatment and adverse-effect background; not the current complete drug list.
- NHLBI living with heart failure — Monitoring and day-to-day care education.
- NHS heart failure June 2026 education — June 2026 national clinical and emergency education.
- NICE NG106 chronic heart failure recommendations — Current NG106 recommendations with 2025 update and 2026 appraisal links; attributed care context.
- NHLBI budget — Financial provenance only.
- NHLBI Gift Fund — Financial provenance only.
- NHS national website funding policy — Financial provenance only.
- NICE audited annual report and accounts 2025–26 — Financial provenance only.
Original clinical pages and their relevant financial disclosures were opened. Guidance, classification, emergency education and independent efficacy are distinct source roles. A full systematic review, complete society donor audit and author-by-author clearance of original treatment trials were not completed.
Last reviewed: October 4, 2026. Educational information, not a diagnosis or personal treatment plan. Use your local emergency service for an emergency.
Have a question — or want us to cover something?
Ask about anything on this page, or request the next deep dive: an ingredient, a supplement, or a health concern. We use published research, evidence syntheses, and regulatory guidance, with clear source links.
One daily research roundup
Get the topics, key findings and links from our new articles in one email. At most one digest a day, only when there is something new.